Company profile
West Island Brands Inc.
OTC: WIBFF · Healthcare · Drug Manufacturers - Specialty & Generic
Canadian filerHQ Toronto, ONReports USD
#810 of 1,418 Healthcare companies by revenuetop-decile growth
EA Score
——FH —DQ —GM —SS 36
v0.1 · 5/100 weight · pillars only
↑ revenue growth (YoY), balance-sheet leverage · ↓ market scale, return on equity
Methodology →Revenue TTM
$3.5M
Rev growth YoY (TTM)
+159.9%
Net income (FY)
-$4.1M
Employees
—
as of 2026-08-28
Market cap
$60.1k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.9M2.3M CAD2021
Net income-$4.1M-5.1M CAD2021
Operating income-$3.8M-4.8M CAD2021
Total assets$4.8M6.1M CAD2021
Liabilities$2.3M2.9M CAD2021
Equity$2.6M3.3M CAD2021
Revenue trend
FY2017 – FY2021 · USD
FY17
FY18
FY19
FY20
FY21
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is West Island Brands Inc.’s revenue?
West Island Brands Inc. booked $1.9M in FY2021 revenue, growing 1950% year over year — faster than 97% of Healthcare companies we track, at a -221.1% net margin.
Peers · Healthcare
Resonate Blends, Inc.——Vycor Medical, Inc.56CPharmaCielo Ltd.40DBioRegenx, Inc.30DBeleave Inc.——Bionik Laboratories Corp.——Key facts
CEODaniel Bélanger
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersToronto, ON
ExchangeOTC: WIBFF
Employees—
IPO date2015-02-23
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.